Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies

2016/02/10 by Yan Chen, Yan Q. Chen, Thomas G. Pottanat +4 · 10 citations
Medicine · Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · #Monoclonal and Polyclonal Antibodies Research #Biosimilars and Bioanalytical Methods #Advanced Biosensing Techniques and Applications

paper · doi:10.1016/j.jim.2016.02.008

Citations

• An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug
• Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
• Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

Cited by

• A sensitive and drug tolerant assay for detecting anti-AAV9 antibodies using affinity capture elution
• Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity
• Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. [europepmc]
• Trastuzumab immunogenicity development in patients' sera and in laboratory animals. [europepmc]
• Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. [europepmc]
• Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology. [europepmc]
• Current Analytical Strategies for Antibody-Drug Conjugates in Biomatrices. [europepmc]
• Development, Validation and Application of a Bridging ELISA for Detection of Antibodies against GQ1001 in Cynomolgus Monkey Serum. [europepmc]
• Population Pharmacokinetics and Pharmacodynamics of Fepixnebart (LY3016859) and Epiregulin in Patients with Chronic Pain. [europepmc]
• Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease. [europepmc]